Guselkumab
Brand: Tremfya
Immunomodulator
IL-23 (p19) monoclonal antibody
Pharmacokinetics
| Half-life | 16 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | Dosed at week 0 and 4, then every 8 weeks; linear PK typical for IgG1 mAbs. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
URTIs, headache, injection site reactions, arthralgia, diarrhea
Contraindications:
Active serious infections
Precautions:
Avoid live vaccines; monitor for infections; possible slight increase in GI infections